Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson Published 2024-02-27 Download video MP4 360p Download video MP4 720p Recommendations 05:47 Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz 06:03 Wholesale inflation rose 0.6% in February, more than expected 04:55 CPC strategist says pushback against carbon tax shows how 'isolated' Trudeau is 47:59 Why EV Sales Are Falling | CNBC Marathon 07:43 Former Treasury Secretary Mnuchin: I'm going to put together a group to buy TikTok 39:51 Exploring Wealthy Alabama 🇺🇸 12:23 Why China, Japan And The Fed Are Shaking Up The $26 Trillion U.S. Treasury Market 12:18 Why Widespread Tech Layoffs Keep Happening Despite A Strong U.S. Economy 04:13 Weight-loss drug frenzy: $100 billion total addressable market opportunity? 05:49 Equities will likely bottom by mid-October, says Voya Investment's Barbara Reinhard 06:01 Trade Tracker: Jim Lebenthal on buying Amazon, 'This is not an expensive stock' 09:52 Pfizer CEO doubles down on 2024 guidance, talks Seagen buy 13:12 Google vs. Google: The internal struggle holding back its AI 03:01 Viking Therapeutics (VKTX) Gains as Patients Lose Weight 32:15 Druckenmiller on How AI is Dominating His Long Portfolio 02:17 Markets are still trying to find under-recognized growth companies, says Thomas Martin 04:52 Those investing in the Russell 2000 are missing the boat on what's happening, says Ritholtz's Brown 09:06 There's no problem with demand, AI is creating more attacks, says Palo Alto Networks CEO 12:03 Jim Cramer on what could be the next $1 trillion stock 18:02 Why Direct-To-Consumer Companies Like Casper, Allbirds And Peloton Are All Struggling